Companies: 10,795·Total market cap: $144.5T
RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc.

REPCFOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$7000
P/E Ratio—
52W High$0.042835
52W Low$0.00001
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

RepliCel Life Sciences Inc. (REPCF) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001205059 · REPCF · OTC · as of Jun 9, 2026

Filing snapshot

422
Total Filings
D
Latest Form
2024-12-16
Most Recent
2010
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001205059 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2023-05-02
Fiscal Year End
May 2, 2023
Accession No.
0001062993-23-009854
Primary Document
form20f.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001205059 · Accession 0001062993-23-009854

Latest Key Filings

6-KQuarterly Report
FORM 6-K
2024-03-20
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
DD
D
2024-12-16
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2024-03-20
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2023-11-30
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2023-10-24
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2023-10-19
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2023-10-04
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2023-09-14
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2023-09-07
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2023-08-30
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2023-08-29
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2023-08-17
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2023-08-10
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2023-05-31
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2023-05-18
View
20-FAnnual Report (Foreign Issuer)
FORM 20-F
2023-05-02
View
Showing 1–15 of 422 filingsForm 4 / 144 hidden

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001205059  |  Exchange: OTC · Healthcare

RepliCel Life Sciences Inc. (OTC: REPCF) has submitted 422 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2010. As a Healthcare sector company with CIK 0001205059, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is RepliCel Life Sciences Inc.'s most comprehensive regulatory disclosure. The most recent RepliCel Life Sciences Inc. 10-K was filed on 2023-05-02 for fiscal year ending 2023. Historical REPCF 10-K annual reports are available from 2002 through 2023.

Investors researching RepliCel Life Sciences Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
→ REPCF Financials→ REPCF Earnings→ REPCF Insider Trades

Frequently Asked Questions

REPCF SEC Filings · 8 questions

RepliCel Life Sciences Inc. (REPCF) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 422 filings and access original documents at no cost. RepliCel Life Sciences Inc.'s CIK is 0001205059.

REPCF SEC filingsRepliCel Life Sciences Inc. SEC documentsfind REPCF 10-K